Comparison of bioengineered human bone construct from four sources of osteogenic cells

Comparison of bioengineered human bone construct from four sources of osteogenic cells
复制标题

DOI:
10.1007/s00776-004-0884-2
复制
发表时间:
2005-01-01
影响因子:
1.7
通讯作者:
Idrus, RBH
Idrus, RBH
中科院分区:
医学4区
文献类型:
--
作者:
Ng, AMH;Bin Saim, A;Idrus, RBH

文献摘要

被引文献

相似文献

据报道,骨祖细胞存在于骨膜、松质骨和皮质骨中。和骨髓,但尚未报道试图鉴定用于骨组织工程的最佳细胞来源。本研究我们的目的是研究来自这四种来源的细胞在体外单层细胞和三维细胞构建体中的细胞倍增时间和成骨细胞特异性标志物表达方面的生长和分化模式。同时,评价了人血浆衍生的纤维蛋白在形成三维骨结构时用作生物材料。我们的研究结果显示,来源于骨膜的骨祖细胞增殖最多,其次是皮质骨,松质骨,然后是骨髓穿刺液。在由骨膜来源的细胞形成的结构中观察到骨形成活性,而在由松质骨和皮质骨来源的细胞形成的结构中观察到钙沉积。虽然在由骨髓来源的骨祖细胞形成的结构中没有观察到矿化活性,但注意到在骨重建的早期阶段会出现组织良好的骨陷窝。扫描电子显微镜评价显示整个纤维蛋白基质中的细胞增殖,表明人纤维蛋白作为生物工程组织支架在非承重部位的可能应用。
Osteoprogenitor cells have been reported to be present in periosteum, cancellous, and cortical bone. and bone marrow but no attempt to identify the best cell source for bone tissue engineering has yet been reported. In this study. we aimed to investigate the growth and differentiation pattern of cells derived from these four sources in terms of cell doubling time and expression of osteoblast-specific markers in both monolayer cells and three-dimensional cell constructs in vitro. In parallel, human plasma derived-fibrin was evaluated for use as biomaterial when forming three-dimensional bone constructs. Our findings showed osteoprogenitor cells derived from periosteum to be most proliferative followed by cortical bone, cancellous bone, and then bone marrow aspirate. Bone-forming activity was observed in constructs formed with cells derived from periosteum, whereas calcium deposition was seen throughout the constructs formed with cells derived from cancellous and cortical bones. Although no mineralization activity was seen in constructs formed with osteoprogenitor cells derived from bone marrow, well-organized lacunae as would appear in the early phase of bone reconstruction were noted. Scanning electron microscopy evaluation showed cell proliferation throughout the fibrin matrix, suggesting the possible application of human fibrin as the bioengineered tissue scaffold at non-load-bearing sites.